debrisoquin has been researched along with phenacetin in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (66.67) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Idle, JR; Lancaster, R; Mahgoub, AA; Sloan, TP; Smith, RL | 1 |
| Idle, JR; Lancaster, R; Mahgoub, A; Sloan, TP; Smith, RL | 1 |
| Idle, JR; Smith, RL | 1 |
| Kallio, J | 1 |
| McLean, S; Veronese, ME | 1 |
| Park, BK | 1 |
| Boobis, AR; Davies, DS; Edwards, RJ; Sesardic, D | 1 |
| Davis, GG; Distlerath, LM; Guengerich, FP; Martin, MV; Reilly, PE; Wilkinson, GR | 1 |
| Al-Dabbagh, SG; Idle, JR; Smith, RL | 1 |
| Eichelbaum, M | 2 |
| Cooper, M; Devonshire, HW; Idle, JR; Kong, I; Sloan, TP; Smith, RL | 1 |
3 review(s) available for debrisoquin and phenacetin
| Article | Year |
|---|---|
Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.
Topics: Debrisoquin; Drug Therapy; Genetics; Guanidines; Humans; Hydroxylation; Kinetics; Oxidation-Reduction; Pharmaceutical Preparations; Phenacetin; Phenotype; Stereoisomerism | 1979 |
[Heritable polymorphisms in oxidative drug metabolism].
Topics: Animals; Cytochrome P-450 Enzyme System; Debrisoquin; Humans; In Vitro Techniques; Mephenytoin; Nifedipine; Oxidation-Reduction; Pharmaceutical Preparations; Phenacetin; Polymorphism, Genetic; Rats | 1990 |
[Genetic polymorphism of oxidative drug metabolism. Therapeutic and toxicologic implications].
Topics: Adrenergic beta-Antagonists; Cytochrome P-450 Enzyme System; Debrisoquin; Humans; Hydroxylation; Mephenytoin; Oxidation-Reduction; Perhexiline; Pharmaceutical Preparations; Phenacetin; Phenformin; Phenotype; Phenytoin; Polymorphism, Genetic; Receptors, Drug; Sparteine | 1983 |
12 other study(ies) available for debrisoquin and phenacetin
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Genetically determined defcts of oxidation at carbon centres of drugs.
Topics: Carbon; Debrisoquin; Genes, Recessive; Guanidines; Humans; Hydroxylation; Oxidation-Reduction; Pharmaceutical Preparations; Phenacetin | 1978 |
Polymorphism of carbon oxidation of drugs and clinical implications.
Topics: Acetaminophen; Carbon; Debrisoquin; Female; Guanidines; Humans; Hydroxylation; Male; Oxidation-Reduction; Phenacetin; Phenotype; Polymorphism, Genetic | 1978 |
Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.
Topics: Acetaminophen; Adult; Biotransformation; Debrisoquin; Female; Humans; Male; Oxidation-Reduction; Phenacetin; Phenotype | 1991 |
Metabolic basis of adverse drug reactions.
Topics: Acetaminophen; Acetylation; Adrenergic beta-Antagonists; Adult; Age Factors; Child; Debrisoquin; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Enzyme Induction; Enzyme Inhibitors; Humans; Perhexiline; Pharmaceutical Preparations; Phenacetin; Phenformin; Phenotype; Polymorphism, Genetic; Succinylcholine | 1986 |
A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking.
Topics: Animals; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Debrisoquin; Enzyme Induction; Female; Humans; Kinetics; Liver; Mice; Mice, Inbred BALB C; Molecular Weight; Oxidoreductases; Phenacetin; Rats; Smoking | 1988 |
Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism.
Topics: Amino Acids; Animals; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Ethanolamines; Humans; Hydroxylation; Immunoelectrophoresis; Kinetics; Liver; Male; Mixed Function Oxygenases; Oxidation-Reduction; Oxidoreductases; Phenacetin; Polymorphism, Genetic; Rats; Rats, Inbred Strains; Stereoisomerism | 1985 |
Animal modelling of human polymorphic drug oxidation--the metabolism of debrisoquine and phenacetin in rat inbred strains.
Topics: Animals; Biotransformation; Debrisoquin; Female; Hydroxylation; Isoquinolines; Models, Biological; Oxidation-Reduction; Phenacetin; Phenotype; Polymorphism, Genetic; Rats; Rats, Inbred Strains; Species Specificity | 1981 |
The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition.
Topics: Acetaminophen; Adult; Dealkylation; Debrisoquin; Female; Humans; Hydroxylation; Male; Oxidation-Reduction; Phenacetin; Phenotype; Time Factors | 1983 |
Polymorphic drug oxidation in humans.
Topics: Cytochrome b Group; Cytochrome P-450 Enzyme System; Cytochromes b5; Debrisoquin; Humans; Mephenytoin; Microsomes, Liver; Oxidation-Reduction; Pharmaceutical Preparations; Phenacetin; Phenformin; Phenytoin; Polymorphism, Genetic; Sparteine; Tolbutamide | 1984 |